|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYRIB |
Gene summary for CYRIB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYRIB | Gene ID | 51571 |
| Gene name | CYFIP related Rac1 interactor B | |
| Gene Alias | BM-009 | |
| Cytomap | 8q24.21 | |
| Gene Type | protein-coding | GO ID | GO:0000266 | UniProtAcc | A0A024R9G4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51571 | CYRIB | CA_HPV_1 | Human | Cervix | CC | 2.84e-03 | 1.84e-01 | 0.0264 |
| 51571 | CYRIB | N_HPV_2 | Human | Cervix | N_HPV | 3.16e-03 | 1.85e-01 | -0.0131 |
| 51571 | CYRIB | CCI_1 | Human | Cervix | CC | 1.93e-06 | -5.20e-01 | 0.528 |
| 51571 | CYRIB | CCI_2 | Human | Cervix | CC | 8.18e-06 | -5.20e-01 | 0.5249 |
| 51571 | CYRIB | CCI_3 | Human | Cervix | CC | 5.72e-09 | -5.20e-01 | 0.516 |
| 51571 | CYRIB | CCII_1 | Human | Cervix | CC | 7.66e-13 | -5.20e-01 | 0.3249 |
| 51571 | CYRIB | Tumor | Human | Cervix | CC | 6.17e-26 | -5.20e-01 | 0.1241 |
| 51571 | CYRIB | sample1 | Human | Cervix | CC | 1.45e-10 | -5.20e-01 | 0.0959 |
| 51571 | CYRIB | sample3 | Human | Cervix | CC | 2.98e-28 | -5.20e-01 | 0.1387 |
| 51571 | CYRIB | H2 | Human | Cervix | HSIL_HPV | 2.98e-28 | -5.20e-01 | 0.0632 |
| 51571 | CYRIB | L1 | Human | Cervix | CC | 3.46e-14 | -5.20e-01 | 0.0802 |
| 51571 | CYRIB | T1 | Human | Cervix | CC | 5.04e-24 | -5.20e-01 | 0.0918 |
| 51571 | CYRIB | T2 | Human | Cervix | CC | 1.97e-05 | -5.20e-01 | 0.0709 |
| 51571 | CYRIB | T3 | Human | Cervix | CC | 4.34e-27 | -5.20e-01 | 0.1389 |
| 51571 | CYRIB | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.85e-17 | 3.24e-01 | 0.0155 |
| 51571 | CYRIB | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.28e-26 | 6.02e-01 | -0.1808 |
| 51571 | CYRIB | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.22e-05 | 3.08e-01 | 0.0216 |
| 51571 | CYRIB | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.66e-36 | 8.32e-01 | -0.0811 |
| 51571 | CYRIB | HTA11_78_2000001011 | Human | Colorectum | AD | 2.21e-33 | 8.00e-01 | -0.1088 |
| 51571 | CYRIB | HTA11_347_2000001011 | Human | Colorectum | AD | 1.60e-53 | 8.72e-01 | -0.1954 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00509203 | Cervix | CC | regulation of chemotaxis | 51/2311 | 223/18723 | 8.03e-06 | 1.86e-04 | 51 |
| GO:00224099 | Cervix | CC | positive regulation of cell-cell adhesion | 61/2311 | 284/18723 | 9.30e-06 | 2.11e-04 | 61 |
| GO:00300419 | Cervix | CC | actin filament polymerization | 45/2311 | 191/18723 | 1.20e-05 | 2.54e-04 | 45 |
| GO:19030397 | Cervix | CC | positive regulation of leukocyte cell-cell adhesion | 53/2311 | 239/18723 | 1.37e-05 | 2.74e-04 | 53 |
| GO:00508708 | Cervix | CC | positive regulation of T cell activation | 49/2311 | 216/18723 | 1.51e-05 | 2.97e-04 | 49 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:19029048 | Cervix | CC | negative regulation of supramolecular fiber organization | 40/2311 | 167/18723 | 2.39e-05 | 4.17e-04 | 40 |
| GO:00313339 | Cervix | CC | negative regulation of protein-containing complex assembly | 35/2311 | 141/18723 | 3.41e-05 | 5.55e-04 | 35 |
| GO:00308339 | Cervix | CC | regulation of actin filament polymerization | 40/2311 | 172/18723 | 4.90e-05 | 7.40e-04 | 40 |
| GO:00106399 | Cervix | CC | negative regulation of organelle organization | 68/2311 | 348/18723 | 7.40e-05 | 1.03e-03 | 68 |
| GO:00080649 | Cervix | CC | regulation of actin polymerization or depolymerization | 42/2311 | 188/18723 | 8.60e-05 | 1.15e-03 | 42 |
| GO:00308328 | Cervix | CC | regulation of actin filament length | 42/2311 | 189/18723 | 9.76e-05 | 1.27e-03 | 42 |
| GO:00108218 | Cervix | CC | regulation of mitochondrion organization | 34/2311 | 144/18723 | 1.27e-04 | 1.58e-03 | 34 |
| GO:00514948 | Cervix | CC | negative regulation of cytoskeleton organization | 37/2311 | 163/18723 | 1.57e-04 | 1.88e-03 | 37 |
| GO:00019135 | Cervix | CC | T cell mediated cytotoxicity | 15/2311 | 49/18723 | 5.81e-04 | 5.52e-03 | 15 |
| GO:00024564 | Cervix | CC | T cell mediated immunity | 26/2311 | 109/18723 | 6.39e-04 | 5.97e-03 | 26 |
| GO:20001147 | Cervix | CC | regulation of establishment of cell polarity | 9/2311 | 22/18723 | 7.19e-04 | 6.49e-03 | 9 |
| GO:00027118 | Cervix | CC | positive regulation of T cell mediated immunity | 16/2311 | 56/18723 | 8.97e-04 | 7.74e-03 | 16 |
| GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
| GO:00026967 | Cervix | CC | positive regulation of leukocyte activation | 72/2311 | 409/18723 | 1.13e-03 | 9.31e-03 | 72 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |